Lansoprazolo Sun Pharma Italia Srl

Lansoprazole, the active ingredient in Lansoprazolo Sun Pharma Italia Srl, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is employed in the management of acid‑related disorders such as gastro‑oesophageal reflux disease, peptic ulcer disease and eradication regimens for Helicobacter pylori infection.

GNH USA supplies Lansoprazolo Sun Pharma Italia Srl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality and regulatory compliance.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal conditions.

- Gastro‑oesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing by suppressing gastric acid secretion. - Helicobacter pylori eradication: used as part of combination therapy to improve bacterial eradication rates. - Erosive esophagitis: aids mucosal recovery by maintaining a higher gastric pH.

Lansoprazole is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate headache occurring shortly after initiation. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: transient feeling of queasiness. - Abdominal pain: discomfort in the upper abdomen. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Hepatic enzyme elevation: increased ALT or AST levels. - Hypomagnesemia: low serum magnesium with prolonged use. - Interstitial nephritis: kidney inflammation causing reduced function. - Stevens‑Johnson syndrome: rare skin and mucous membrane disorder.

Before prescribing lansoprazole, clinicians should consider several safety aspects.

- Assess renal function: adjust therapy in patients with severe renal impairment. - Monitor for drug interactions: especially with clopidogrel, atazanavir, and high‑dose methotrexate. - Use with caution in the elderly: increased risk of bone fractures and infections. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lansoprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption, leading to sub‑therapeutic antiviral levels. - High‑dose methotrexate: increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring closer coagulation monitoring. - Digoxin: possible rise in serum concentrations, necessitating dose adjustment. - Diazepam: may increase plasma levels, enhancing sedative effects.